Rab Peter, Shirinskiy Igor J, Kimmeyer Michael, Macken Arno A, Calamita Andrea G, Colombini Antonio G, Buijze Geert Alexander, Lafosse Thibault
Alps Surgery Institute, Clinique Générale Annecy, Annecy, France.
Department of Sports Orthopaedics, Technical University of Munich, Ismaninger Strasse 22, Munich, 81675, Germany.
BMC Musculoskelet Disord. 2025 Sep 23;26(1):855. doi: 10.1186/s12891-025-09199-2.
To compare the clinical and radiographic outcomes after full-thickness RC repair with and without performing augmentation with a bioinductive collagen implant (BCI).
Consecutive patients who underwent primary repair of a full-thickness supraspinatus tear between 05/2021 and 11/2023 were retrospectively identified. Patients at elevated risk for retear were defined by biological, radiographic, and intraoperative risk factors. Those who underwent repair with or without concomitant augmentation using a BCI and who had both clinical and radiographic follow-up at 1 year postoperatively were matched in a 1:1 ratio according to age, sex, body mass index, tear size, smoking status, diabetes, and American Society of Anesthesiologists physical status classification. Range of motion (ROM) as well as patient-reported outcome measures (Auto-Constant-Score (CS), American Shoulder and Elbow Surgeons (ASES) Score, Subjective Shoulder Value (SSV), and Visual Analog Scale (VAS) for pain) were recorded. Magnetic resonance imaging performed at 1 year postoperatively was analyzed and the presence of retear was recorded.
In total, 149 patients with a radiographic and clinical follow-up at 1 year postoperatively were identified. Of these, 23 patients with BCI augmentation were matched to 23 patients without placement of BCI (48% female, 59.2 ± 8.4 years at surgery). A retear occurred in 5 patients (21.7%) in the BCI augmentation group and in 3 patients (13.0%) in the control group (p = 0.72). No significant difference was reported regarding the CS (77 [71-83] vs. 76 [63-81], p = 0.5), ASES Score (92 [82-98] vs. 90 [84-95], p = 0.8), SSV (90 [80-100] vs. 90 [88-95], p = 0.9), VAS for pain (p = 0.74), or ROM between the groups.
In this retrospective matched cohort of patients at elevated risk for retear, augmentation of full-thickness RC repair with a BCI was not associated with a reduced retear rate. Moreover, no significant differences regarding clinical and functional outcome were found between the two groups.
III - Retrospective case series with a matched control group.
比较全层肩袖修复时使用和不使用生物诱导胶原蛋白植入物(BCI)进行增强的临床和影像学结果。
回顾性纳入2021年5月至2023年11月间接受原发性全层冈上肌撕裂修复的连续患者。根据生物学、影像学和术中危险因素确定再撕裂风险较高的患者。将使用或未使用BCI进行增强修复且术后1年有临床和影像学随访的患者,按照年龄、性别、体重指数、撕裂大小、吸烟状况、糖尿病和美国麻醉医师协会身体状况分级进行1:1匹配。记录活动范围(ROM)以及患者报告的结局指标(自动常量评分(CS)、美国肩肘外科医师学会(ASES)评分、主观肩关节评分(SSV)和疼痛视觉模拟量表(VAS))。分析术后1年进行的磁共振成像,并记录再撕裂的情况。
共确定149例术后1年有影像学和临床随访的患者。其中,23例接受BCI增强的患者与23例未植入BCI的患者匹配(48%为女性,手术时年龄59.2±8.4岁)。BCI增强组有5例患者(21.7%)发生再撕裂,对照组有3例患者(13.0%)发生再撕裂(p = 0.72)。两组在CS(77[71 - 83]对76[63 - 81],p = 0.5)、ASES评分(92[82 - 98]对90[84 - 95],p = 0.8)、SSV(90[80 - 100]对90[88 - 95],p = 0.9)、疼痛VAS(p = 0.74)或ROM方面均未报告有显著差异。
在这个再撕裂风险较高的回顾性匹配队列患者中,使用BCI增强全层肩袖修复与降低再撕裂率无关。此外,两组在临床和功能结局方面未发现显著差异。
III - 带有匹配对照组的回顾性病例系列研究。